Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case
Background. Insufficient efficacy or intolerance of the first TNF-α inhibitor in patients with juvenile idiopathic arthritis (JIA) is an indication for the appointment of a second inhibitor. Golimumab is a new TNF-α inhibitor registered for treating JIA under pediatric indications. Clinical Case Des...
Saved in:
Main Authors: | Ekaterina V. Denisova (Author), Ekaterina I. Alexeeva (Author), Tatyana M. Dvoryakovskaya (Author), Margarita A. Soloshenko (Author), Anna V. Mamutova (Author), Kseniya B. Isayeva (Author), Anna N. Fetisova (Author) |
---|---|
Format: | Book |
Published: |
"Paediatrician" Publishers LLC,
2018-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE EXPERIENCE OF SWITCHING TO THE SECOND TNF INHIBITOR IN A PATIENT WITH SEVERE JUVENILE POLYARTHRITIS AND RESISTANCE TO THE FIRST TNF-BLOCKER
by: Ekaterina I. Alexeeva, et al.
Published: (2017) -
Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate
by: Ekaterina Alexeeva, et al.
Published: (2019) -
Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study
by: Ekaterina I. Alexeeva, et al.
Published: (2019) -
Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data
by: Ekaterina Alexeeva, et al.
Published: (2023) -
PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY
by: Ekaterina I. Alexeeva, et al.
Published: (2018)